ADARx Closes $446M IPO and $89M AbbVie Private Placement
ADRX is trading near its 52-week low of $18.5 (8.6% above the low).
Summary
ADARx Pharmaceuticals closed its $446.3 million IPO and an $89.3 million private placement with AbbVie, raising approximately $535.6 million in total gross proceeds.
Key Events · Financing and Capital Events · ADRX
-
IPO and Private Placement Closed
ADARx closed its IPO of 26,250,000 shares at $17.00 per share for approximately $446.3 million in gross proceeds, plus a concurrent private placement of 5,255,542 shares to AbbVie for approximately $89.3 million.
-
AbbVie Takes 4.9% Stake
AbbVie purchased 5,255,542 shares at the IPO price of $17.00, resulting in approximately 4.9% ownership of outstanding shares following the closing.
-
Placement Agent Fees
The company paid a placement agent fee equal to 2.0% of the total purchase price for the private placement, with J.P. Morgan, Morgan Stanley, TD Securities, UBS, and LifeSci Capital acting as agents.
-
Amended Charter Authorizes 1B Shares
The amended and restated certificate of incorporation authorizes 999,999,999 shares of common stock and 10,000,000 shares of preferred stock, providing substantial headroom for future issuance.
Analysis · ADRX · Life Sciences
ADARx Pharmaceuticals closed its upsized IPO and a concurrent private placement with AbbVie, raising approximately $535.6 million in aggregate gross proceeds. The IPO priced at $17.00 per share, and AbbVie purchased 5,255,542 shares at the same price, giving AbbVie approximately 4.9% ownership. The company also adopted an amended and restated certificate of incorporation authorizing up to 999,999,999 shares of common stock, providing substantial headroom for future issuance. This capital raise significantly strengthens the company's balance sheet as it advances its RNA-editing pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADRX was trading at $20.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.50 to $23.21. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.